Repligen (RGEN) Tops Q4 EPS by 16c

Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.81, $0.16 better than the analyst estimate of $0.65. Revenue for the quarter came in at $186.5 million versus the consensus estimate of $179.29 million.

GUIDANCE:

Repligen sees FY2022 EPS of $3.21-$3.30, versus the consensus of $3.15. Repligen sees FY2022 revenue of $800-830 million, versus the consensus of $801.46 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Hyperscale Data launches $300M at-the-market stock offering
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS